Research has shown that HER2 significantly boosts CDK4/6 activity through phosphorylated Rb (pRb) in HER2+ breast cancer, suggesting the potential responsiveness of HER2+ breast cancer to CDK4/6i [87]. The gene discussed is ERBB2; the disease is breast cancer.